Join to access to all OVN content. Join for Free

Results for 'high-income countries'

Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials
OVN Avatar Shubham Sharma, J Connor Wells, Wilma M Hopman, Joseph C Del Paggio, Bishal Gyawali, Nazik Hammad, Annette E Hay, Christopher M Booth
Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials

cancer, clinical trials, research funding, Canada, high-income countries

This document reviews Canadian involvement in oncology randomized controlled trials (RCTs) from 2014-2017, comparing them to those from other high-income countries (HICs). Canada contributed to 155 (24%) of 636 HIC-led RCTs. Canadian RCTs focused more on palliative care (72%) compared to 62% in …

Apr 13th • 10 mins read

Association Between US Drug Price and Measures of Efficacy for Oncology Drugs Approved by the US Food and Drug Administration From 2015 to 2020
OVN Avatar Miloš D. Miljković, MD, MSc, Jordan E. Tuia, BA, Timothée Olivier, MD
Association Between US Drug Price and Measures of Efficacy for Oncology Drugs Approved by the US Food and Drug Administration From 2015 to 2020

Cancer drug pricing, Cancer care costs, Cancer drug efficacy, Progression-free survival, Value-based pricing in oncology, FDA anticancer approvals

The US has worse cancer-related outcomes compared to other high-income countries and has the highest cost of cancer care globally. High costs may be attributed to the improved efficacy of expensive new cancer drugs, though the relationship between cost and benefit is debated. A study found a lin…

Oct 31st • 10 mins read

Related Topics

Loading...